<- Go Home
CohBar, Inc.
CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.
Market Cap
$1.5M
Volume
239.7K
Cash and Equivalents
$6.2M
EBITDA
-$13.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$1.10
52 Week Low
$0.00
Dividend
N/A
Price / Book Value
0.16
Price / Earnings
-0.12
Price / Tangible Book Value
0.16
Enterprise Value
-$10.8M
Enterprise Value / EBITDA
0.83
Operating Income
-$13.1M
Return on Equity
83.97%
Return on Assets
-48.31
Cash and Short Term Investments
$12.3M
Debt
N/A
Equity
$9.5M
Revenue
N/A
Unlevered FCF
-$3.5M
Sector
Biotechnology
Category
N/A